Abstract
The Duffy Antigen/Receptor for Chemokine (DARC) is a seven segment transmembrane protein. It was firstly discovered as a blood group antigen and was the first specific gene locus assigned to a specific autosome in man. It became more famous as an erythrocyte receptor for malaria parasites (Plasmodium vivax and Plasmodium knowlesi), and finally for chemokines. DARC is an unorthodox chemokine receptor as (i) it binds chemokines of both CC and CXC classes and (ii) it lacks the Asp-Arg-Tyr consensus motif in its second cytoplasmic loop hence cannot couple to G proteins and activate their signaling pathways. DARC had also been associated to cancer progression, numerous inflammatory diseases, and possibly to AIDS. In this review, we will summarize important biological data on DARC. Then we shall focus on recent development of the elaboration and analyzes of structural models of DARC. We underline the difficulty to propose pertinent structural models of transmembrane protein using comparative modeling process, and other dedicated approaches as the Protein Blocks. The chosen structural models encompass most of the biochemical data known to date. Finally, we present recent development of protein - protein docking between DARC structural models and CXCL-8 structures. We propose a hierarchal search based on separated rigid and flexible docking.
Keywords: Duffy antigen / receptor for chemokine, CXCL-8, Duffy Binding Protein, chemokines, malaria, Plasmodium vivax
Infectious Disorders - Drug Targets
Title: In Silico Studies on DARC
Volume: 9 Issue: 3
Author(s): Alexandre G. de Brevern, Ludovic Autin, Yves Colin, Olivier Bertrand and Catherine Etchebest
Affiliation:
Keywords: Duffy antigen / receptor for chemokine, CXCL-8, Duffy Binding Protein, chemokines, malaria, Plasmodium vivax
Abstract: The Duffy Antigen/Receptor for Chemokine (DARC) is a seven segment transmembrane protein. It was firstly discovered as a blood group antigen and was the first specific gene locus assigned to a specific autosome in man. It became more famous as an erythrocyte receptor for malaria parasites (Plasmodium vivax and Plasmodium knowlesi), and finally for chemokines. DARC is an unorthodox chemokine receptor as (i) it binds chemokines of both CC and CXC classes and (ii) it lacks the Asp-Arg-Tyr consensus motif in its second cytoplasmic loop hence cannot couple to G proteins and activate their signaling pathways. DARC had also been associated to cancer progression, numerous inflammatory diseases, and possibly to AIDS. In this review, we will summarize important biological data on DARC. Then we shall focus on recent development of the elaboration and analyzes of structural models of DARC. We underline the difficulty to propose pertinent structural models of transmembrane protein using comparative modeling process, and other dedicated approaches as the Protein Blocks. The chosen structural models encompass most of the biochemical data known to date. Finally, we present recent development of protein - protein docking between DARC structural models and CXCL-8 structures. We propose a hierarchal search based on separated rigid and flexible docking.
Export Options
About this article
Cite this article as:
de Brevern G. Alexandre, Autin Ludovic, Colin Yves, Bertrand Olivier and Etchebest Catherine, In Silico Studies on DARC, Infectious Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/1871526510909030289
DOI https://dx.doi.org/10.2174/1871526510909030289 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Important Role of Relaxation Techniques in Immune Functions, Glycemic Control, and Stress in Diabetic Patients with COVID-19: A Review
Current Diabetes Reviews Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs
Current Pharmaceutical Design Apoptosis Following Photodynamic Tumor Therapy: Induction, Mechanisms and Detection
Current Pharmaceutical Design From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Molecular Actions of Polyhalogenated Arylhydrocarbons (PAHs) in Female Reproduction
Current Medicinal Chemistry Hypoxia and Fetal Heart Development
Current Molecular Medicine Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Current Pharmaceutical Design Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Current Topics in Medicinal Chemistry Human Arylamine N-Acetyltransferase 1: A Drug-Metabolizing Enzyme and a Drug Target?
Current Drug Targets Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism
Current Neurovascular Research Nano-Phytosome: A Developing Platform for Herbal Anti-Cancer Agents in Cancer Therapy
Current Drug Targets Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Magnetic Iron Oxide Nanoparticles for Tumor-Targeted Therapy
Current Cancer Drug Targets Editorial (Thematic Issue: Novel Therapeutic Strategies for Castration-resistant Prostate Cancer: Update and Future Perspectives)
Clinical Cancer Drugs Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews